Reviewing Syndax Pharmaceuticals (NASDAQ:SNDX) and Ultragenyx Pharmaceutical (NASDAQ:RARE)

Syndax Pharmaceuticals (NASDAQ:SNDX) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, earnings and profitability.

Valuation & Earnings

This table compares Syndax Pharmaceuticals and Ultragenyx Pharmaceutical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35 million	7.02	-$285.42 million	($2.51)	-5.44
Ultragenyx Pharmaceutical	$673.00 million	2.22	-$575.00 million	($5.84)	-2.60

Syndax Pharmaceuticals has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 4.8% of Syndax Pharmaceuticals shares are owned by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Syndax Pharmaceuticals has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500.

Profitability

This table compares Syndax Pharmaceuticals and Ultragenyx Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%
Ultragenyx Pharmaceutical	-81.79%	N/A	-44.40%

Analyst Ratings

This is a breakdown of recent ratings for Syndax Pharmaceuticals and Ultragenyx Pharmaceutical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1	0	10	0	2.82
Ultragenyx Pharmaceutical	1	11	9	1	2.45

Syndax Pharmaceuticals currently has a consensus price target of $41.80, suggesting a potential upside of 206.23%. Ultragenyx Pharmaceutical has a consensus price target of $33.65, suggesting a potential upside of 121.82%. Given Syndax Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Ultragenyx Pharmaceutical.

Summary

Syndax Pharmaceuticals beats Ultragenyx Pharmaceutical on 8 of the 14 factors compared between the two stocks.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.